Zoetis Valuation
Is 0M3Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0M3Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0M3Q ($168.33) is trading below our estimate of fair value ($198.21)
Significantly Below Fair Value: 0M3Q is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0M3Q?
Other financial metrics that can be useful for relative valuation.
| What is 0M3Q's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$76.34b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9.3x |
| Enterprise Value/EBITDA | 22.9x |
| PEG Ratio | 3.6x |
Price to Earnings Ratio vs Peers
How does 0M3Q's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.6x | ||
GSK GSK | 15.8x | 11.9% | UK£70.7b |
AZN AstraZeneca | 37x | 16.5% | UK£186.8b |
HIK Hikma Pharmaceuticals | 28.7x | 18.0% | UK£4.3b |
HCM HUTCHMED (China) | 32.9x | 17.5% | UK£2.6b |
0M3Q Zoetis | 31.9x | 8.9% | US$76.3b |
Price-To-Earnings vs Peers: 0M3Q is expensive based on its Price-To-Earnings Ratio (31.9x) compared to the peer average (28.6x).
Price to Earnings Ratio vs Industry
How does 0M3Q's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 0M3Q is expensive based on its Price-To-Earnings Ratio (31.9x) compared to the European Pharmaceuticals industry average (24.8x).
Price to Earnings Ratio vs Fair Ratio
What is 0M3Q's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 31.9x |
| Fair PE Ratio | 39.4x |
Price-To-Earnings vs Fair Ratio: 0M3Q is good value based on its Price-To-Earnings Ratio (31.9x) compared to the estimated Fair Price-To-Earnings Ratio (39.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$168.33 | US$213.56 +26.9% | 11.0% | US$248.00 | US$170.00 | n/a | 14 |
| Apr ’25 | US$169.95 | US$220.68 +29.8% | 9.4% | US$260.00 | US$170.00 | n/a | 16 |
| Mar ’25 | US$191.83 | US$221.93 +15.7% | 8.9% | US$260.00 | US$170.00 | n/a | 16 |
| Feb ’25 | US$188.93 | US$220.97 +17.0% | 9.1% | US$255.00 | US$170.00 | n/a | 16 |
| Jan ’25 | US$197.35 | US$214.90 +8.9% | 10.6% | US$255.00 | US$170.00 | n/a | 15 |
| Dec ’24 | US$178.59 | US$212.39 +18.9% | 10.5% | US$255.00 | US$170.00 | n/a | 14 |
| Nov ’24 | US$152.46 | US$217.10 +42.4% | 10.8% | US$260.00 | US$170.00 | n/a | 15 |
| Oct ’24 | US$174.43 | US$218.77 +25.4% | 10.3% | US$260.00 | US$170.00 | n/a | 15 |
| Sep ’24 | US$192.36 | US$216.23 +12.4% | 11.4% | US$260.00 | US$170.00 | n/a | 13 |
| Aug ’24 | US$185.59 | US$213.23 +14.9% | 12.0% | US$260.00 | US$170.00 | n/a | 13 |
| Jul ’24 | US$171.84 | US$213.50 +24.2% | 12.7% | US$260.00 | US$170.00 | n/a | 12 |
| Jun ’24 | US$165.63 | US$214.25 +29.4% | 12.4% | US$260.00 | US$170.00 | n/a | 12 |
| May ’24 | US$176.30 | US$214.08 +21.4% | 12.5% | US$260.00 | US$170.00 | US$158.68 | 12 |
| Apr ’24 | US$164.52 | US$214.92 +30.6% | 12.3% | US$260.00 | US$170.00 | US$169.95 | 12 |
| Mar ’24 | US$167.08 | US$214.92 +28.6% | 12.3% | US$260.00 | US$170.00 | US$191.83 | 12 |
| Feb ’24 | US$165.83 | US$209.70 +26.5% | 13.2% | US$250.00 | US$170.00 | US$188.93 | 12 |
| Jan ’24 | US$147.85 | US$208.91 +41.3% | 14.4% | US$250.00 | US$170.00 | US$197.35 | 11 |
| Dec ’23 | US$157.03 | US$208.91 +33.0% | 14.4% | US$250.00 | US$170.00 | US$178.59 | 11 |
| Nov ’23 | US$151.40 | US$223.36 +47.5% | 10.0% | US$264.00 | US$186.00 | US$152.46 | 11 |
| Oct ’23 | US$150.38 | US$225.64 +50.0% | 10.5% | US$264.00 | US$186.00 | US$174.43 | 11 |
| Sep ’23 | US$158.06 | US$225.64 +42.8% | 10.5% | US$264.00 | US$186.00 | US$192.36 | 11 |
| Aug ’23 | US$180.91 | US$226.09 +25.0% | 10.7% | US$264.00 | US$186.00 | US$185.59 | 11 |
| Jul ’23 | US$172.20 | US$233.50 +35.6% | 10.0% | US$264.00 | US$186.00 | US$171.84 | 10 |
| Jun ’23 | US$166.92 | US$235.45 +41.1% | 11.3% | US$275.00 | US$186.00 | US$165.63 | 11 |
| May ’23 | US$178.50 | US$245.73 +37.7% | 9.0% | US$275.00 | US$186.00 | US$176.30 | 11 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.